| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 9.66 mm | 9.66 mm | 9.66 mm | 9.66 mm | 9.66 mm | 9.66 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 2.77 mm | 1.57 mm | 1.95 mm | 1.99 mm |
| Cash used (since last report) | n/a | n/a | 22.35 mm | 12.70 mm | 15.78 mm | 16.11 mm |
| Cash remaining | n/a | n/a | -12.69 mm | -3.04 mm | -6.13 mm | -6.45 mm |
| Runway (months of cash) | n/a | n/a | -4.6 | -1.9 | -3.1 | -3.2 |
| 13F holders | Current |
|---|---|
| Total holders | 30 |
| Opened positions | 3 |
| Closed positions | 6 |
| Increased positions | 3 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 4.37 bn |
| Total shares | 8.11 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | 2.31 mm | $15.07 mm |
| BLVGF Bellevue | 1.28 mm | $1.80 bn |
| BBBOF BB Biotech | 1.03 mm | $0.00 |
| Biotechnology Value Fund L P | 672.77 k | $303.00 k |
| Silverarc Capital Management | 623.84 k | $876.49 mm |
| K2 HealthVentures Equity Trust | 596.15 k | $2.13 mm |
| BVF | 522.24 k | $733.74 mm |
| Sante Health Ventures I | 469.07 k | $891.00 k |
| Longitude Capital Partners III | 309.82 k | $493.00 k |
| BMO Bank of Montreal | 73.13 k | $642.04 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 Nov 24 | Biotech Target | Common Stock | Sell | Dispose S | No | No | 0.6609 | 1,279,820 | 845.83 k | 0 |
| 27 Sep 24 | Gabriela Gruia | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 1,000 | 1.41 k | 1,000 |
| 27 Sep 24 | Sanders Corazon | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 1,000 | 1.41 k | 1,000 |
| 27 Sep 24 | Hoffmann Dave | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 1,000 | 1.41 k | 1,000 |
| 27 Sep 24 | Lalande Kevin M. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.41 | 1,000 | 1.41 k | 1,000 |
| 2 Apr 24 | Biotech Target | Common Warrants Common Stock | Buy | Acquire P | No | No | 0.125 | 769,334 | 96.17 k | 769,334 |
| 2 Apr 24 | Biotech Target | Prefunded Warrants Common Stock | Buy | Acquire P | No | No | 2.349 | 134,667 | 316.33 k | 134,667 |
